In this Phase 2b/3 trial, the efficacy and safety of the investigational drug bexotegrast will be investigated in volunteers with IPF to assess its potential impact on slowing or halting disease progression over a 52-week treatment period by reducing scar formation (fibrosis) of the lungs.
Bexotegrast is an investigational drug that is currently being studied in clinical trials as a potential treatment for IPF.
Bexotegrast is an oral, small molecule, dual-selective inhibitor of integrins αvβ6 and αvβ1 designed to block TGF-β mediated fibroblast-to-myofibroblast transition and collagen synthesis.
Please select your region: